If the higher dose MPL repeats the same up to almost 5 year life extension that was shown in Phase 1 with an excellent safety profile, wouldn’t approval be a given? Even if these figures in Phase 2/3 weren’t as “good” as our Phase 1?
Ann: Board Changes, page-175
-
- There are more pages in this discussion • 76 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $82.15M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.5¢ | $47.49K | 229.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 197620 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 89808 | 4 |
View Market Depth
| Last trade - 11.39am 26/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |